QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 effector-therapeutics-declared-in-default-on-75m-oxford-finance-loan

On June 25, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received written notice from Oxford Finance LLC (“Oxford”) that e...

 why-effector-therapeutics-eftr-shares-are-down-over-70

EFFECTOR Therapeutics shares are trading lower by 74% during Monday's session. The company announced that it has terminated...

 effector-therapeutics-q1-2024-gaap-eps-216-beats-217-estimate-reports-cash-runway-into-q1-of-2025

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of...

 dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...

 why-staar-surgical-shares-are-trading-higher-by-around-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...

 nasdaq-surges-1-conagra-brands-posts-upbeat-earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...

 cancer-focused-effector-therapeutics-shelves-development-of-lung-cancer-candidate-after-disappointing-data

eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib sh...

 dow-jumps-over-100-points-us-jobless-claims-increase-to-221000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the marke...

 effector-therapeutics-announces-topline-results-of-phase-2-kickstart-trial-of-tomivosertib-combined-with-pembrolizumab-in-non-small-cell-lung-cancer

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION